Multiple Sclerosis
Conditions
Keywords
multiple sclerosis, estroprogestins, interferon-beta, sex hormones, MRI
Brief summary
Clinical and experimental evidences suggests an immunomodulatory effect of sex hormones in multiple sclerosis. The role of oral estroprogestins in the pathogenesis and in the clinical course of the disease is actually unknown. The aim of the study is to investigate safety and tolerability of association of estroprogestins in two different doses with interferon-beta 1a in patients with relapsing-remitting multiple sclerosis.
Detailed description
Phase 2, randomised, single blind, three arms study. Follow-up of 24 months. The study will include relapsing-remitting multiple sclerosis female patients. Patients will be equally randomised into three groups: 1) patients treated with IFN-beta 1a (44 mcg for three times a week), 2) patients treated with IFN-beta 1a and lower-dose estroprogestins (desogestrel 150 mcg, etinilestradiol 20 mcg), 3) patients treated with IFN-beta 1a and higher-dose estroprogestins (desogestrel 25 mcg, etinilestradiol 40 mcg). Safety and tolerability of the treatment will be evaluated using neurological examination and MRI analysis. A complete neurological examination (with EDSS) will be performed at month 0, 6, 12, 18 and 24. MRI examination will be assessed at baseline and at month 12 and 24. In the same day of MRI examination we'll collect blood samples for hormonal analysis (we'll measure sex hormones in the follicular and in the luteal phase of a single menstrual cycle). During the follow-up patients will be evaluated also with: MS-Functional Composite at month 0, 6, 12, 18, 24; neuropsychological evaluation at month 0, 12, 24; Fatigue Severity Scale at month 0, 12, 24; Hamilton Depression Scale at month 0, 12, 24; Quality of Life scale (MSQOL54) at month 0, 12, 24.
Interventions
DRUGestroprogestins
Sponsors
S. Andrea Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Female patients * Clinically definite relapsing-remitting MS according to the McDonald criteria * Age between 18-40 y.o. * EDSS from 0 to 4.0, inclusive
Exclusion criteria
* History of migraine or thromboembolic events * Reproductive system disorders * Pregnancy or suspension of pregnancy within 12 months prior to randomisation * Prior use of estroprogestins within the last 3 months prior to randomisation * Prior use of immunosuppressive drugs within the last 12 months prior to randomisation * Prior use of immunomodulating drugs within the last 6 months prior to randomisation * Prior use of corticosteroids within the last 3 months prior to randomisation * Have clinical relapse 30 days prior to randomisation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety assessment at 6, 12, 18 and 24 months, including adverse events, physical examination and laboratory parameters | — |
| Relapse rate at 6, 12, 18 and 24 months, | — |
| EDSS progression at 12 and 24 months, | — |
| MS functional composite score at 12 and 24 months, | — |
Secondary
| Measure | Time frame |
|---|---|
| Hamilton scale for depression score at 0, 12, 24 months | — |
| Number and volume of new gad-enhancing lesions at 12 and 24 months | — |
| Fatigue Severity Scale score at 0, 12, 24 months | — |
| MS Quality of Life scale score(MSQOL54)at 0, 12, 24 months | — |
| Number of new T1 and T2 lesions at 12 and 24 months | — |
| Brain volume changes at 12 and 24 months | — |
| Neuropsychological examination at 0, 12, 24 months | — |
Countries
Italy
Contacts
Primary ContactCarlo Pozzilli, MD
Backup ContactFabiana Marinelli, MD
Outcome results
None listed